Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma
BEIJING & BOSTON–(BUSINESS WIRE)–#ADC–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company... Read more.
Aptia, Leading New Pensions and Employee Health and Benefits Specialist, Formally Launches with 1,100 Clients and Supporting 7 Million People
LONDON & BOSTON–(BUSINESS WIRE)–Aptia (the “Company”), a dedicated pension, health and benefits administration specialist, today announced its... Read more.
NanoPhoria appoints Dr. Suman Shirodkar as Chair and Prof. Michael Davidson as Non-Executive Member of the Board of Directors
MILAN–(BUSINESS WIRE)–NanoPhoria, a pre-clinical stage biotech company that is developing a versatile, non-viral drug delivery platform based on inorganic... Read more.
Thinking Local Is Key for EU’s Cloud Service Providers
European providers are balancing data sovereignty with cloud scalability in an environment marked by increased regulations, ISG Provider Lens™ report says LONDON–(BUSINESS... Read more.
Fisker Names Angel Salinas as Chief Accounting Officer
LOS ANGELES–(BUSINESS WIRE)–#EVs—Fisker Inc. (NYSE: FSR) (“Fisker”), driven by a mission to create the world’s most emotional and sustainable... Read more.
Logitech Announces Date for Release of Third Quarter Results for Fiscal Year 2024
LAUSANNE, Switzerland & SAN JOSE, Calif.–(BUSINESS WIRE)–Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it expects to release... Read more.
Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock
Novel biomarker-guided Phase 3 registration trial in septic shock with an enrichment strategy-based patient selection. Historic paradigm shift in Primary endpoint:... Read more.
Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock
Novel biomarker-guided Phase 3 registration trial in septic shock with an enrichment strategy-based patient selection. Historic paradigm shift in Primary endpoint:... Read more.
B2C2 Appoints Thomas Restout as Group CEO
LONDON & TOKYO & JERSEY CITY, N.J.–(BUSINESS WIRE)–#B2C2–B2C2, the leading institutional digital asset liquidity provider, today announces... Read more.
B2C2 Appoints Thomas Restout as Group CEO
LONDON & TOKYO & JERSEY CITY, N.J.–(BUSINESS WIRE)–#B2C2–B2C2, the leading institutional digital asset liquidity provider, today announces... Read more.